What is Androgen Deprivation Therapy Market?
The growth of the world androgen deprivation therapy market is driven by the rising cases and deaths of prostate cancer, innovative technologies, advancing care expenditure and facilities, increasing international awareness and demand for higher treatment. The R&D bodies are actively dwelling to develop novel androgen deprivation therapy for cancer. The approval of the latest medicine has additionally propelled the androgen deprivation therapy market growth. However, the market growth is constrained by the resistance developed throughout the treatments, facet effects like hot flashes, disfunction, low bone density, insulin resistance, etc. Androgen deprivation therapy is ineffective for hormone-refractory prostate cancer. The high expenses and poor compensation of treatment expenses hinder the market growth. Although, the international androgen deprivation therapy market is anticipated to grow in addition due to the increasing cases of prostate cancer, rising R&D and care facilities.
The market study is being classified by Type (Luteinizing Hormone-Releasing Hormone (LHRH) agonists, LHRH antagonists, Antiandrogens and Others) and major geographies with country level break-up.
Abbott Laboratories (United States), Genentech Inc. (United States), GlaxoSmithKline Plc (United Kingdom), Immunomedics Inc. (United States), Allergan plc (India), Amgen (United States), Bayer AG (Germany), AstraZeneca (United Kingdom), Johnson & Johnson (United States), Pfizer (United States) and Sanofi (France) are some of the key players profiled in the study.
The prevalence of Prostate Cancer has increased the market for Androgen Deprivation Therapy. The rise in the expenditure on healthcare has also increased the market along with the rising geriatric population. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Androgen Deprivation Therapy market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Androgen Deprivation Therapy market by Type, Application and Region.
On the basis of geography, the market of Androgen Deprivation Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Expenditure on Healthcare
- High Prevalence of The Prostate Cancer
- Increased Demand for Better and Efficient Technique
- Rapid Adoption of The Therapy
- High Cost Associated with The Therapy
- Improved Technology and Massive Research Investments
- Increasing Government Initiatives
- Lack of Awareness
- Poor Reimbursement of The Treatment Expense
Key Target AudienceProviders of Androgen Deprivation Therapy, Governmental and Regulatory bodies, End-Users and Potential Investors
Frequently Asked Questions (FAQ):
1. Which factors would majorly drive the Androgen Deprivation Therapy Market?
"Increased Expenditure on Healthcare
" is seen as one of major growth factors of Androgen Deprivation Therapy Market in years to come.
2. Can we have customized study for Androgen Deprivation Therapy Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.